Parsifal Capital Management LP Has $96.36 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Parsifal Capital Management LP lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 29.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,372,001 shares of the company’s stock after selling 1,860,970 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 8.0% of Parsifal Capital Management LP’s investment portfolio, making the stock its 6th biggest holding. Parsifal Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $96,359,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. increased its stake in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $4,966,000. Asset Management One Co. Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock valued at $23,368,000 after acquiring an additional 1,045,305 shares during the last quarter. Finally, Capital Wealth Planning LLC raised its holdings in Teva Pharmaceutical Industries by 8.8% during the fourth quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company’s stock worth $5,435,000 after acquiring an additional 20,016 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several recent research reports. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $24.43.

Teva Pharmaceutical Industries Stock Down 2.7%

TEVA stock opened at $17.48 on Wednesday. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The business’s 50 day simple moving average is $15.22 and its 200 day simple moving average is $17.44. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $19.82 billion, a PE ratio of -12.06, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.48 earnings per share. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.